Cancer Organoid

Pancreatic Cancer Organoid

Tumor-Infiltrating Lymphocytes (TILs) are predominantly found in the microenvironment of tumors, including various types of lymphocytes that have infiltrated in and around tumor tissues.
Among them, CD8+ cytotoxic T cells and CD4+ helper T cells are major components.
Our approach involves isolating and expanding TILs from a patient’s tumor tissue, then evaluating the efficacy of anticancer agents in a tumor microenvironment containing cancer organoids and TILs.


Price	1784€+ Login to see price
Organism	Human
Product Type	Organoid
Tissue	Pancreatic ducts, Pancreatic endocrine cells
Disease	Pancreatic cancer

Applications

Oncology

Small Molecule

Antibody

Cancer Vaccine

mRNA

Immune Cell

TME-CAF

Immuno Oncology

Macrophage

Regulatory T Cell

Tumor-Infiltrating Lymphocyte

Cytotoxic T Cell

Description

Revolutionize Pancreatic Cancer Research with Our 3D Organoids

Step into the future of oncology with Lambda AF Solution’s Human Pancreatic Cancer Organoids. Crafted with cutting-edge 3D culture technology, these organoids bring the complex environment of pancreatic cancer right to your lab. Perfect for delving into tumor heterogeneity and enhancing drug testing—pioneering precision medicine starts here!

Pancreatic cancer organoid

	H&E	ANXA1	ANXA10	ANXA13
Cancer tissue
Cancer tissue
Cancer organoid
Cancer organoid

Genetic mutation

Unlock the essence of precision in cancer treatment with our PC organoids, mirroring the genetic markers of pancreatic cancer.
Experience the future of testing your drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing.
Dive into a new era of oncology, where your individuality guides our innovation.

Top mutated genes

Performing WES analysis on 7pancreatic cancer (hPC) organoid samples, the top 25 gene mutations were observed to be noticeably present across the samples, indicating a high level of mutation.
According to these results, it appears that conducting experiments using the various types of pancreatic cancer samples we possess will likely yield results similar to those observed in actual human cases.

Pancreatic cancer mutation PPI Network

Using hPC Organoid, we statistically analyze the correlation between genetic mutations in proteins and protein-to-protein databases to confirm the associative relationships of genes

Drug response

Embrace personalized medicine with our cutting-edge platform:
Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses. Transform the standard with us—where your medication’s potential is as unique as you are.

We have confirmed varying efficacy among patients when treating pancreatic cancer organoids derived from patients with representative chemotherapeutic agents such as gemcitabine and paclitaxel.
This underscores the potential for selecting personalized drugs tailored to each patient.
Furthermore, matching these treatments with patients genetic profiles could significantly aid in selecting appropriate chemotherapy agents. We aim to contribute to the advancement of personalized cancer therapy based on these findings.

Patient-specific drug reactivity

Each patient displays individual variations in drug response patterns, making it possible to explore the optimal medication for each patient. Explore patient-specific drug reactivity using our state-of-the-art platform. Assess your medication’s efficacy compared to standard treatments in optimal conditions and uncover customized therapeutic responses.